By analyzing existing technical and fundamental indicators between Logicbio Therapeutics and China, you can compare the effects of market volatilities on both companies' prices and check if they can diversify away market risk if combined in one of your portfolios. You can also utilize pair trading strategies for matching a long position in China with a short position in Logicbio Therapeutics. Check out our
pair correlation module for more information.
Let's begin by analyzing the assets.
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Logicbio Therapeutics has an asset utilization ratio of 291.18 percent. This suggests that the company is making $2.91 for each dollar of assets. An increasing asset utilization means that Logicbio Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.
Out of tens of thousands of stocks, funds, and ETFs that trade on global exchanges each represent an individual company which you can analyze using comparative analysis. To determine which one of the two entities, such as LogicBio or Apogee is a better fit for your portfolio, analyzing a few basic fundamental indicators is a good first step.
How important is LogicBio Therapeutics's Liquidity
LogicBio Therapeutics
financial leverage refers to using borrowed capital as a funding source to finance LogicBio Therapeutics ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. LogicBio Therapeutics financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to LogicBio Therapeutics' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of LogicBio Therapeutics' financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the
breakdown between LogicBio Therapeutics's total debt and its cash.
Correlation Between LogicBio and Apogee Enterprises
In general, Delisted Stock analysis is a method for investors and traders to make individual buying and selling decisions. Stock correlation analysis is also essential because it can help investors realize that they may not be as diversified as they think. Risk management strategies are usually required to make sure all portfolios are properly aligned against their risk tolerance level. You can consider holding LogicBio Therapeutics together with similar or unrelated positions with a negative correlation. For example, you can also add Apogee Enterprises to your portfolio. If Apogee Enterprises is not perfectly correlated to LogicBio Therapeutics it will diversify some of the market risks out of the positively correlated stocks in your portfolio. However, the disadvantage of this sort of hedging is that it can potentially affect your investment returns throughout market cycles. When LogicBio Therapeutics, for example, performs excellent and delivers stable returns, the negatively correlated position you locked in as a hedge may drag your returns down.
Are you currently holding both LogicBio Therapeutics and Apogee Enterprises in your portfolio? Please note if you are using this as a pair-trade strategy between LogicBio Therapeutics and Apogee Enterprises, watch out for correlation discrepancy over time. Relying on the historical price correlations and assuming that it will not change may lead to short-term losses. Please check
pair correlation details between LOGC and APOG for more information.
What is driving LogicBio Therapeutics Investor Appetite?
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include product or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Revenue Breakdown
Now, let's check Logicbio Therapeutics revenue. Based on the latest financial disclosure, Logicbio Therapeutics reported 7.76
M of revenue. This is 99.9% lower than that of the Healthcare sector and 98.96% lower than that of the
Biotechnology industry. The revenue for all United States stocks is 99.92% higher than that of Logicbio Therapeutics. As for China Res we see revenue of 33.39
B, which is much higher than that of the Biotechnology
| LOGC | 7.76 Million | 0.0227 |
| Sector | 742.91 Million | 2.18 |
| CRHKY | 33.39 Billion | 97.8 |
Over 3 percent rise for Logicbio Therapeutics. What does it mean for investors?
Current Information Ratio is up to -0.04. Price may slip again. Logicbio Therapeutics is displaying above-average volatility over the selected time horizon. Investors should scrutinize Logicbio Therapeutics independently to ensure intended market timing strategies are aligned with expectations about Logicbio Therapeutics volatility. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Logicbio Therapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Logicbio Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.
Our Final Take On Logicbio Therapeutics
Whereas some other companies within the biotechnology industry are still a little expensive, even after the recent corrections, Logicbio Therapeutics may offer a potential longer-term growth to investors. The inconsistency in the assessment between current Logicbio valuation and our trade advice on Logicbio Therapeutics is due to the recent market swings and your selection of investing horizon. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Logicbio Therapeutics.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Vlad Skutelnik is a Macroaxis Contributor. Vlad covers stocks, funds, cryptocurrencies, and ETFs that are traded in North America, focusing primarily on fundamentals, valuation and market volatility. He has many years of experience in fintech, predictive investment analytics, and risk management.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of LogicBio Therapeutics. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com
